Diffusion Weighted Imaging (DWI) - IVIM

Quibim

Quibim’s Diffusion Weighted Imaging (DWI) – IVIM automatically performs intra-voxel incoherent motion (IVIM) analysis to detect changes in the microstructure of tissues to assess cancer processes in clinical practice and research. The tool allows the differentiation of pure diffusion changes due to variations in the vascular component and offers additional information complementary to conventional ADC results. This suite is aimed at the characterization of tumoral processes to support early detection, diagnosis, treatment response evaluation and follow-up of patients
Product specifications Information source: Vendor
Last updated: May 17, 2020
General
Product name Diffusion Weighted Imaging (DWI) - IVIM
Company Quibim
Subspeciality Abdomen, Breast, Neuro
Modality MR
Disease targeted Solid tumors, Breast cancer, Prostate cancer, Rectal cancer, Endometrial cancer, Liver cancer, Gliomas, Meningiomas, Lymphomas, Ischemic injuries
Key-features Parametric maps, Diffusion coefficient, Psuedodiffusion coefficient, Perfusion fraction
Suggested use During: interactive decision support (shows abnormalities/results only on demand), report suggestion, Need to draw ROI
Data characteristics
Population Follow-up of tumoral staging and treatment response
Input MR DWI (DIffusion Weighted Imaging) with multiple b-values
Input format
Output One-page structured report: parametric maps, histograms and statistics summary of the diffusion coefficient, pseudodiffusion coefficient, perfusion fraction.
Output format DICOM Secondary Capture / PDF
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically after drawing ROI
Processing time 1 - 10 minutes
Certification
CE
Certified, Class IIa , MDD
FDA
No or not yet
Market presence
On market since 01-2019
Distribution channels
Countries present (clinical, non-research use) 10
Paying clinical customers (institutes) 5+
Research/test users (institutes) 15+
Pricing
Pricing model License
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Martí-Bonmatí L, Ramírez-Fuentes C, Alberich-Bayarri Á, Ruiz-Llorca C. State-of-the-art of bone marrow imaging in multiple myeloma. Curr Opin Oncol. 2015 Nov; 27(6): 540-50.